company background image
UCB logo

UCB ENXTBR:UCB Stock Report

Last Price

€136.30

Market Cap

€25.9b

7D

2.1%

1Y

12.5%

Updated

19 Apr, 2025

Data

Company Financials +

UCB SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for UCB
Historical stock prices
Current Share Price€136.30
52 Week High€198.95
52 Week Low€118.10
Beta0.33
1 Month Change-24.15%
3 Month Change-25.32%
1 Year Change12.46%
3 Year Change24.30%
5 Year Change65.49%
Change since IPO44,568.61%

Recent News & Updates

Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All

Apr 18
Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All

UCB SA's (EBR:UCB) Share Price Is Still Matching Investor Opinion Despite 25% Slump

Apr 17
UCB SA's (EBR:UCB) Share Price Is Still Matching Investor Opinion Despite 25% Slump

We Think UCB (EBR:UCB) Can Manage Its Debt With Ease

Mar 28
We Think UCB (EBR:UCB) Can Manage Its Debt With Ease

Recent updates

Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All

Apr 18
Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All

UCB SA's (EBR:UCB) Share Price Is Still Matching Investor Opinion Despite 25% Slump

Apr 17
UCB SA's (EBR:UCB) Share Price Is Still Matching Investor Opinion Despite 25% Slump

We Think UCB (EBR:UCB) Can Manage Its Debt With Ease

Mar 28
We Think UCB (EBR:UCB) Can Manage Its Debt With Ease

UCB's (EBR:UCB) Earnings Are Of Questionable Quality

Mar 07
UCB's (EBR:UCB) Earnings Are Of Questionable Quality
author-image

BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology

Mar 02 UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 02
UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing

Feb 28
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing

Is UCB (EBR:UCB) A Risky Investment?

Dec 24
Is UCB (EBR:UCB) A Risky Investment?

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22
Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10
These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28
Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15
Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Shareholder Returns

UCBBE PharmaceuticalsBE Market
7D2.1%2.5%4.2%
1Y12.5%-16.7%2.5%

Return vs Industry: UCB exceeded the Belgian Pharmaceuticals industry which returned -16.2% over the past year.

Return vs Market: UCB exceeded the Belgian Market which returned 3% over the past year.

Price Volatility

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.4%
10% most volatile stocks in BE Market8.4%
10% least volatile stocks in BE Market2.6%

Stable Share Price: UCB's share price has been volatile over the past 3 months compared to the Belgian market.

Volatility Over Time: UCB's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

€209.78
FV
35.0% undervalued intrinsic discount
11.96%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
2 days ago author updated this narrative

About the Company

FoundedEmployeesCEOWebsite
19259,215Jean-Christophe Tellierwww.ucb.com

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

UCB SA Fundamentals Summary

How do UCB's earnings and revenue compare to its market cap?
UCB fundamental statistics
Market cap€25.90b
Earnings (TTM)€1.07b
Revenue (TTM)€6.15b

24.3x

P/E Ratio

4.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UCB income statement (TTM)
Revenue€6.15b
Cost of Revenue€1.75b
Gross Profit€4.40b
Other Expenses€3.34b
Earnings€1.07b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.60
Gross Margin71.52%
Net Profit Margin17.31%
Debt/Equity Ratio28.1%

How did UCB perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

25%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/19 08:13
End of Day Share Price 2025/04/17 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

UCB SA is covered by 50 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark van der GeestABN AMRO Bank N.V.
Kamla SinghAlphaValue
Brian BourdotBarclays